NOV 28, 2019 8:25 AM PST

Immunotherapy Drug Shows Promise for Treating Advanced Prostate Cancer

WRITTEN BY: Annie Lennon

By the end of the year, an estimated 175,000 men in the United States will have been diagnosed with prostate cancer. Now, researchers from the UK have found a new way using immunotherapy to slow down the progression of the disease in its advanced stages, potentially adding an extra 2 years of lifespan to patients. 

The immunotherapy drug, known as pembrolizumab, works by blocking the activity of a molecule called PD-1, a protein that stops cells from identifying and tackling inflamed tissues and cancer cells. By blocking this protein, the drug allows the immune system to unleash T cells that are then able to combat both inflamed tissues and cancer cells. 

Already used to tackle other cancers such as melanoma, a new study by The Institute of Cancer Research, London, shows that it may be effective in treating advanced prostate cancer too. Conducted via a Phase II clinical trial, the drug was administered to 258 men with the disease who had become resistant to both androgen deprivation therapy and docetaxel chemotherapy. 

In total, the researchers found that 5% of the participants saw their tumours shrink or disappear, with 19% showing other evidence of tumor response. They also saw the average survival time following treatment among a group of 166 patients with very advanced stages of the disease and high levels of prostate-specific antigen (PSA) increase to 8.1 months. Meanwhile, a second group whose PSA levels were lower, even though the disease had spread to the bone, lived for an average of 14.1 months after treatment. 

In particular, the researchers found the most dramatic responses in patients whose tumors had mutations in genes that repair DNA. Known as “super-responders”, Johann de Bono, Regius Professor of cancer research at The Institute of Cancer Research, London, said, “Our study has shown that a small proportion of men with very advanced prostate cancer are super responders to immunotherapy and could live for at least two years and possibly considerably longer.”

Professor Paul Workman, chief executive of The Institute of Cancer Research, London, added, “Immunotherapy has had tremendous benefits for some cancer patients and it's fantastic news that even in prostate cancer, where we don't see much immune activity, the proportion of men are responding well to treatment….'It's encouraging to see testing for DNA repair mutations may identify some patients who are more likely to respond, and I'm keen to see how the new, larger trial in this group of patients plays out.”


Sources: Melanoma Research Alliance, Daily Mail and BBC News

About the Author
  • Annie graduated from University College London and began traveling the world. She is currently a writer with keen interests in genetics, psychology and neuroscience; her current focus on the interplay between these fields to understand how to create meaningful interactions and environments.
You May Also Like
JAN 14, 2020
Drug Discovery & Development
JAN 14, 2020
Promising Treatment for Dementia: Antibiotics
A class of antibiotics, known as the ‘aminoglycosides’ may serve as a promising treatment for frontotemporal dementia—according to resear...
JAN 20, 2020
Cell & Molecular Biology
JAN 20, 2020
Using Modified Red Blood Cells As a Drug Delivery System
For a drug to be effective, it has to get to the right place to exert its impact....
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
Acid-Reflux Drugs May Negatively Impact Breast Cancer Survivors
Many of us have taken some form of an acid-reflux drug—especially after a meal that causes discomfort. However, now researchers are indicating that s...
FEB 10, 2020
Cancer
FEB 10, 2020
New hope for KRAS-mutant pancreatic cancers
A study published recently in the journal Cancer Research showcases the findings from new research on pancreatic cancer. The study was led by Frank Mc...
FEB 17, 2020
Cancer
FEB 17, 2020
Listening in on cancer cells
Research published today in Nature Methods reports a new technique of “listening” to cancer cells. While it may sound odd (no pun intended...
FEB 21, 2020
Health & Medicine
FEB 21, 2020
Frequent Cannabis Use Could Affect Driving Safety
A new study suggests that heavy marijuana users have the potential to be dangerous drivers. However, hazardous driving appears to be isolated to users who ...
Loading Comments...